Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome
…, A Clarke, D Cassavar, D Dion, H Haught… - Circulation, 2016 - Am Heart Assoc
Background— Less than one-third of smokers hospitalized with an acute coronary syndrome
(ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-…
(ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-…
Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide …
AJ Burger, U Elkayam, MT Neibaur, H Haught… - The American journal of …, 2001 - Elsevier
Ventricular arrhythmias are common in patients with congestive heart failure (CHF) and may
be exacerbated by positive inotropic therapy. Because human B-type natriuretic peptide (…
be exacerbated by positive inotropic therapy. Because human B-type natriuretic peptide (…
Subjective social status and well-being: The role of referent abstraction
Subjective social status (SSS) has been shown to predict well-being and mental health, above
and beyond objective social status (OSS). However, little is known about the factors that …
and beyond objective social status (OSS). However, little is known about the factors that …
Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital
…, N Srivastava, A Clarke, D Cassavar, D Dion, H Haught… - Cmaj, 2018 - Can Med Assoc
BACKGROUND: Patients who continue to smoke after acute coronary syndrome are at
increased risk of reinfarction and death. We previously found use of varenicline to increase …
increased risk of reinfarction and death. We previously found use of varenicline to increase …
[HTML][HTML] Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
…, C Liang, M Neibaur, WH Haught… - … England Journal of …, 2000 - Mass Medical Soc
Background Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has
beneficial hemodynamic effects in patients with decompensated congestive heart failure. We …
beneficial hemodynamic effects in patients with decompensated congestive heart failure. We …
Torsemide vs furosemide among patients with new-onset vs worsening chronic heart failure: a substudy of the TRANSFORM-HF randomized clinical trial
…, A Chen, D Wojdyla, J Vilaro, H Haught… - JAMA …, 2024 - jamanetwork.com
Importance Differences in clinical profiles, outcomes, and diuretic treatment effects may
exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). …
exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). …
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham …
…, A Gutierrez, P Hardesty, P Hartung, WH Haught… - The Lancet, 2020 - thelancet.com
Background Catheter-based renal denervation has significantly reduced blood pressure in
previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal…
previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal…
Examining Daoist Big-Five leadership in cross-cultural and gender perspectives.
YT Lee, H Haught, K Chen, S Chan - Asian American Journal of …, 2013 - psycnet.apa.org
Based on Daoist philosophy and previous research (ie, Lee, 2003; Lee, Han, Byron, & Fan,
2008; Y.-T. Lee, Yang, & Wang, 2009; also see Watts, 1975), a Daoist model of leadership …
2008; Y.-T. Lee, Yang, & Wang, 2009; also see Watts, 1975), a Daoist model of leadership …
Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial
…, YA Lev, P William, AL Eberly, SS Gottleib, WH Haught… - JAMA, 2023 - jamanetwork.com
Importance Although furosemide is the most commonly used loop diuretic in patients with
heart failure, some studies suggest a potential benefit for torsemide. Objective To determine …
heart failure, some studies suggest a potential benefit for torsemide. Objective To determine …
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International …
…, H Krasa, CA Zimmer, G Frivold, WH Haught… - Journal of the American …, 2008 - jacc.org
… Tolvaptan increased urine output by 3 h in a dose-dependent manner (p < 0.0001), without
… Patients received their daily dose of concomitant background medications at least 2 h before …
… Patients received their daily dose of concomitant background medications at least 2 h before …
